New Chief Medical Officer for Cardio3 Biosciences

Warren Sherman has more than three decades of experience in the cardiovascular and cell therapy fields

Dr Warren Sherman

Dr Warren Sherman takes over as Chief Medical officer at Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative, protective and reconstructive therapies, on 1 November.

In this new role, Sherman will leverage his expertise in the cardiovascular and cell therapy fields to support the development of the Belgian company's pipeline, both in cell therapies and cardiovascular diseases.

Sherman has more than 30 years’ experience in the field of cardiology, with a focus on cell-based therapies for post myocardial infarction and heart failure.

Before joining Cardio3 BioSciences, Sherman was at the Columbia University Medical Centre in New York, where he served in a number of capacities.

Sherman founded the Cardiovascular Research Foundation’s International Conference on Cell Therapy for Cardiovascular Disease (IC3D). Started in 2004, this annual conference gathers leaders from the international community who present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.

Companies